Potential of microRNA based diagnostics and therapeutics in glioma: a patent review

Mondal, Indranil; Kulshreshtha, Ritu

doi:10.1080/13543776.2021.1837775

Cited by 20 publications

(17 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brain gliomas are the most common primary malignant tumors in the central nervous system, presenting with an increasing mortality rate. Several patients present with an OS time of less than 2 years ( Mondal and Kulshreshtha, 2021 ; Petridis et al, 2021 ; Tanabe et al, 2021 ; Tu et al, 2021 ). Wang et al (2020c) found that the upregulation of LINC01116 in glioma cells is related to poor prognosis.…”

Section: Expression and Clinical Characteristics Of Linc01116 In Various Cancer Typesmentioning

confidence: 99%

Promising Advances in LINC01116 Related to Cancer

Xu¹,

Yu²,

Zhang³

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are RNAs with a length of no less than 200 nucleotides that are not translated into proteins. Accumulating evidence indicates that lncRNAs are pivotal regulators of biological processes in several diseases, particularly in several malignant tumors. Long intergenic non-protein coding RNA 1116 (LINC01116) is a lncRNA, whose aberrant expression is correlated with a variety of cancers, including lung cancer, gastric cancer, colorectal cancer, glioma, and osteosarcoma. LINC01116 plays a crucial role in facilitating cell proliferation, invasion, migration, and apoptosis. In addition, numerous studies have recently suggested that LINC01116 has emerged as a novel biomarker for prognosis and therapy in malignant tumors. Consequently, we summarize the clinical significance of LINC01116 associated with biological processes in various tumors and provide a hopeful orientation to guide clinical treatment of various cancers in future studies.

show abstract

Section: Expression and Clinical Characteristics Of Linc01116 In Various Cancer Typesmentioning

confidence: 99%

Promising Advances in LINC01116 Related to Cancer

Xu¹,

Yu²,

Zhang³

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…As promising agents that could inhibit the expression of downstream target mRNAs, miRNAs play a critical role in carcinogenesis through regulating different targets’ expressions. Various studies have indicated that miRNAs can be efficient biomarkers of glioma and used as therapeutic targets/agents [ 50 – 52 ]. In this study, miR-1297 has been predicted as an upstream regulatory miRNA for ADM.…”

Section: Discussionmentioning

confidence: 99%

miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)

Cheng

et al. 2022

J Transl Med

View full text Add to dashboard Cite

Background Gliomas account for about 80% of all malignant brain and other central nervous system (CNS) tumors. Temozolomide (TMZ) resistance represents a major treatment hurdle. Adrenomedullin (ADM) has been reported to induce glioblastoma cell growth. Methods Cell viability was measured using the CCK-8 assay. The apoptosis analysis was performed using the Annexin V-FITC Apoptosis Detection Kit. The mitochondrial membrane potential was determined by JC-1 staining. A nude mouse tumor assay was used to detect tumor formation. Hematoxylin and eosin (H&E) and immunohistochemical (IHC) staining were performed in tissue sections. Activation of Akt and Erk and expression of apoptosis-related proteins were determined by immunoblotting. Results ADM expression has been found upregulated in TMZ -resistant glioma samples based on bioinformatics and experimental analyses. Knocking down ADM in glioma cells enhanced the suppressive effects of TMZ on glioma cell viability, promotive effects on cell apoptosis, and inhibitory effects on mitochondrial membrane potential. Moreover, ADM knockdown also enhanced TMZ effects on Bax/Bcl-2, Akt phosphorylation, and Erk1/2 phosphorylation. Bioinformatics and experimental investigation indicated that miR-1297 directly targeted ADM and inhibited ADM expression. miR-1297 overexpression exerted similar effects to ADM knockdown on TMZ-treated glioma cells. More importantly, under TMZ treatment, inhibition of miR-1297 attenuated TMZ treatment on glioma cells; ADM knockdown partially attenuated the effects of miR-1297 inhibition on TMZ-treated glioma cells. Conclusions miR-1297 sensitizes glioma cells to TMZ treatment through targeting ADM. The Bax/Bcl-2, Akt, and Erk1/2 signaling pathways, as well as mitochondrial functions might be involved.

show abstract

“…We provide the first evidence that preoperative serum miR-4297 probably serves as a valuable predictor for glioma grade and prognosis in a sex-specific manner. For decades, flourishing studies have demonstrated miRNAs get involved in the occurrence and development of glioma, and thereafter serum miRNAs could be surrogated as reliable biomarkers for glioma diagnosis and prognosis ( 8 , 9 ). However, for the moment, there have been no widespread applications for potential miRNAs from the bench to the bedside.…”

Section: Discussionmentioning

confidence: 99%

“…There were 33 low-grade gliomas (LGGs), characterized by diffuse astrocytoma (21) and oligodendroglioma (12). A total of 81 high grade gliomas (HGGs) were listed as follows: anaplastic astrocytoma (13), anaplastic oligodendroglioma (9), and glioblastoma (59).…”

Section: Baseline Clinical Characteristics and Serum Mir-expressionmentioning

confidence: 99%

“…MiRNAs-based glioma research have been extensively carried out throughout the last decade. There has been a wealth of data implicating blood-sample-based miRNAs would be promising markers for glioma grades classification and prognostic evaluation ( 7 – 9 ). However, to the best of our knowledge, there is no definite application of miRNAs for glioma clinical management.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum microRNA-4297 is a sex-specific predictive biomarker of glioma grade and prognosis

Huang²,

Xie³

et al. 2022

Front. Neurol.

View full text Add to dashboard Cite

BackgroundGliomas account for nearly 80% of brain cancers, tending to occur more frequently in men with adverse outcomes. Emerging microRNAs have been positioned as promising predictors for glioma's histological grade and prognosis. However, there have been few studies concerning the sex-biased impacts on the clinical approach for the potential microRNA-4297 (miR-4297).MethodsWe utilized GSE139031micro-RNAs profiling to analyze serum miR-4297 expression in glioma. A total of 114 newly diagnosed glioma patients at the First Affiliated Hospital of Fujian Medical University from January 2017 to February 2021 were recruited and prospectively followed up. The association of miR-4297 levels with glioma grade and prognosis was investigated. Luciferase reporter gene assays and genotype analyses were carried out to explore the potential mechanism of sexually dimorphic miR-4297 in glioma.ResultsSerum miR-4297 levels were notably down-regulated in glioma. Besides, serum miR-4297 levels were positively associated with the high grades, which were exclusively present for females. The positive correlations of miR-4297 with O6-methylguanine-DNA methyltransferase (MGMT) protein and mean platelet volume were also observed in females. IDH-mutant females had decreased miR-4297. Median PFS time for females with miR-4297 ≥ 1.392 was distinctly shorter than those with miR-4297 <1.392 (12.3 months vs. 42.89 months, p = 0.0289). Based on multivariate logistic regression, miR-4297-based equation model was established as FHGRS. AU-ROC analysis revealed FHGRS exhibited a robust performance in predicting high-grade glioma in females (p < 0.001), whereas there was no such relationship in males. Furthermore, the MGMT-3'UTR variant rs7896488 in the specific binding region of miR-4297 was correlated with prognosis.ConclusionOur study uncovers sex-dependent characterization of serum miR-4297 in predicting glioma grade and the relapse risk for female patients, which underscores the clinical benefits of sex-specific analysis in non-coding RNA research.

show abstract

Potential of microRNA based diagnostics and therapeutics in glioma: a patent review

Cited by 20 publications

References 40 publications

Promising Advances in LINC01116 Related to Cancer

Promising Advances in LINC01116 Related to Cancer

miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)

Serum microRNA-4297 is a sex-specific predictive biomarker of glioma grade and prognosis

Contact Info

Product

Resources

About